Schering Corporation

Tattanahali L Nagabhushan

Stuart W McCombie

Doris P Schumacher

George H Miller

John C Tang

David Naveh

Michael R Ostrander

Jerome Schwartz

Active recombinant human IL-4 is purified from a crude fermentation broth of a secreted E. coli mutant by subjecting said solution to selective chromatogrphy on a zinc-chelating agarose column at pH 7.2 in a buffer containing a high concentration of sodium chloride, i.e., about 1M sodium chloride, washing first with a phosphate buffer at pH 7.2 containing 1.0M sodium chloride then with a buffer containing 10% glycerol and eluting at pH 5.0. The resulting purified active recombinant human IL-4 solution is further treated by cation exchange chromatography, concentration by diafiltration up to 20 mg/mL and size exclusion gel chromatography using a citrate buffer at pH 4.5.

Purification of human interleukin-4 from a secreted escherichia coli

A novel sequence of highly selective chemical reactions for conversion of 3-Aryl-2-propyn-1-ols into cis-1-Aryl-3-fluoro-1-propene and into D,L-(threo)-1-Aryl-2-acylamido-3-fluoro-1-propanols is disclosed. Preparation of D-(threo)-1-Aryl-2-acylamido-3-fluoro-1-propanol antibacterial agents including the D-(threo)-3-fluoro-3-deoxy derivatives of chloramphenicol and thiamphenicol is also disclosed.

Preparation of (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols

A process for the conversion of aristeromycin into cyclaradine via. The stereoselective reduction of a 3',5'-di-O-protected-2'-keto derivative of aristeromycin is disclosed.

Conversion of aristeromycin into cyclaradine

Intermediates for preparation of

Treatment of viral infections with combinations of cyclaradine and interferon and compositions and kits used therein are disclosed.

Growing community of inventors

Parsippany, NJ, United States of America

Tattanahali L Nagabhushan